Inhalable Biologics Market Forecast 2026–2030 Highlighting Expansion Across Industries

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Inhalable Biologics Market In 2026 And 2030?

The inhalable biologics market size has seen swift expansion in recent years. It is anticipated to increase from $3.22 billion in 2025 to $3.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.7%. The growth observed in the historical period stems from various factors, including the rising prevalence of respiratory diseases, the limitations inherent in injectable biologics, advancements in inhalation device technology, a broadening biologics pipeline, and an increase in hospital-based respiratory care.

The inhalable biologics market size is anticipated to undergo swift expansion over the next few years. It is projected to achieve a value of $6.67 billion by 2030, with a compound annual growth rate (CAGR) of 15.6%. The drivers for this growth during the forecast period include an increase in chronic respiratory disorders, the broadening of inhalable biologics’ applications beyond respiratory conditions, a growing patient preference for non-invasive therapies, enhancements in formulation stability, and increased investments in pulmonary drug delivery research. Key trends anticipated in the forecast period are the expansion of pulmonary delivery for systemic biologics, the rising utilization of dry powder inhalers for biologics, an increased focus on targeted lung drug delivery, the growing development of inhalable monoclonal antibodies, and the adoption of patient-friendly non-invasive biologic therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24253&type=smp

What Major Factors Are Driving The Inhalable Biologics Market Forward?

The escalating prevalence of respiratory ailments is projected to fuel the expansion of the inhalable biologics market moving forward. Respiratory conditions denote illnesses and disorders that impact the lungs and other elements of the respiratory system, including the airways, nasal passages, and the lungs themselves. The widespread occurrence of these conditions is attributed to increasing air pollution, which worsens issues such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and other pollutants. Inhalable biologics prove beneficial for respiratory conditions by providing targeted treatment directly to the lungs, thereby lessening inflammation and enhancing lung function with fewer systemic side effects. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, COPD comprised 3.6% of the total disease burden and 50% of the respiratory disease burden. Therefore, the rise in respiratory conditions significantly contributes to the growth of the inhalable biologics market.

Which Segments Define The Inhalable Biologics Market Segment Structure?

The inhalable biologics market covered in this report is segmented –

1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types

2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications

Subsegments:

1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins

2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines

3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies

4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics

5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics

What Trends Are Influencing The Inhalable Biologics Market?

Major companies operating in the inhalable biologics market are directing their efforts towards developing innovative solutions, such as inhaled insulin, to enhance patient compliance and achieve rapid glycemic control. Inhaled insulin is a type of insulin administered into the bloodstream through the lungs via inhalation, as opposed to injections or insulin pumps. This technique involves inhaling a powdered or aerosolized form of insulin, which subsequently gets absorbed through the lungs and quickly enters the bloodstream to aid in regulating blood sugar levels. For instance, in February 2025, Cipla Limited, an India-based pharmaceutical company, obtained regulatory approval from the Central Drugs Standard Control Organization for Afrezza, globally recognized as the fastest inhaled insulin. This product presents a revolutionary, needle-free option for adults suffering from type 1 and type 2 diabetes. This ultra-rapid-acting insulin begins working within 12 to 15 minutes of inhalation, closely replicating the body’s natural insulin response to meals and thereby improving blood sugar management. The inhaled insulin offers a more comfortable alternative to multiple daily injections, especially beneficial for patients experiencing injection anxiety and thereby improving adherence to insulin therapy.

Who Are The Established Players Within The Inhalable Biologics Market?

Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation

Get The Full Inhalable Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/inhalable-biologics-global-market-report

Which Region Holds The Highest Market Share In The Inhalable Biologics Market?

North America was the largest region in the inhalable biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Inhalable Biologics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/inhalable-biologics-global-market-report

Browse Through More Reports Similar to the Global Inhalable Biologics Market 2026, By The Business Research Company

Inhalable Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Inhalation Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Inhalation Anesthesia Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795